$A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma$
QR Code

QR Code

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

# Objective To evaluate the cost-effectiveness of brentuximab vedotin in patients with R/R sALCL from a UK NHS perspective. # Methods A partitioned survival model used clinical outcomes for brentuximab vedotin from the pivotal phase-2 single-arm trial of brentuximab vedotin in 58 patients with R/R...

Full description

Saved in:

Bibliographic Details
Main Authors:	Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally
Format:	Article
Language:	English
Published:	Columbia Data Analytics, LLC 2016-10-01
Series:	Journal of Health Economics and Outcomes Research
Online Access:	https://doi.org/10.36469/9820
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS
by: A. S. Kolbin, et al.
Published: (2017-05-01)

Assessment of the efficiency of Brentuximab Vedotin in patients with pulmonary Hodgkin Lymphoma by the mean of neutrophil to lymphocyte ratio
by: Gokhan Erdem, et al.
Published: (2018-04-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials
by: Yue Yang, et al.
Published: (2025-07-01)

Exceptional outcome: CD-30-positive relapsed enteropathy-associated T-cell lymphoma (EATL) treated with brentuximab vedotin alone, showing significant improvement in weight and albumin levels in Type II refractory coeliac disease: a case report
by: Kainat Memon, et al.
Published: (2025-07-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma
by: Pukiat, Sulada, et al.
Published: (2012)

Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma
by: Fernández, Karen S., et al.
Published: (2012)

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
by: I. N. Dyakov, et al.
Published: (2022-07-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis
by: Mohamed Nazem Alibrahim, et al.
Published: (2025-05-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis
by: Magdalena Witkowska, et al.
Published: (2025-01-01)

Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD‐1 blockade
by: Thomas M. Kuczmarski, et al.
Published: (2025-05-01)

To the issue of differential diagnosis of Hodgkin lymphoma and T-phenotype anaplastic large-cell lymphoma (ALCL)
by: A. A. Semenova, et al.
Published: (2022-11-01)

Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma
by: Filomena Emanuela Laddaga, et al.
Published: (2025-04-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
by: E. V. Chernyshova, et al.
Published: (2017-01-01)

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
by: Evgenii Shumilov, et al.
Published: (2025-08-01)

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study
by: Evgenii Shumilov, et al.
Published: (2025-08-01)

Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.
by: Ya-Ting Yang, et al.
Published: (2016-01-01)

Anaplastic Large Cell Lymphoma with Generalized Skin Lesion in Childhood: Clinical Case
by: Timur T. Valiev, et al.
Published: (2020-12-01)

Implant-associated anaplastic large T-cell lymphoma (BIA-ALCL): case report
by: Antônio de Pádua Peppe, et al.
Published: (2024-07-01)

Breast implant-associated anaplastic large cell lymphoma: a diagnostic challenge
by: Ana Paula De-Azambuja, et al.
Published: (2020-03-01)

Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults
by: N. E. Konoplya, et al.
Published: (2023-09-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Breast implant-associated anaplastic large-cell lymphoma: a systematic literature review
by: Daniel Sundfeld Spiga Real, et al.
Published: (2019-12-01)

CASES OF PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA TREATED WITH SYSTEMIC OR LOCAL THERAPY
by: Müzeyyen Aslı Ergözoplu, et al.
Published: (2025-07-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis
by: Alexander Biederstädt, et al.
Published: (2025-07-01)

Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study
by: Leyre Bento, et al.
Published: (2025-07-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

Teclistamab for heavily pretreated relapsed / refractory POEMS syndrome
by: Alexis Talbot, et al.
Published: (2025-07-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)